A CLINICAL-STAGE biotechnology company established by The University of Queensland (UQ) and Emory University, based in Atlanta, Georgia, to develop novel cancer supportive care and anticancer therapies has raised US$16 million in series A investment.
The university said the investment from the Brandon Capital-managed Medical Research Commercialisation Fund and Uniseed will enable the company, called QUE Oncology, to develop its leading drug candidate Q-122 and progress its preclinical pipeline.
UQ Vice-Chancellor and President Professor Peter Hj said QUE's success was built on the strong relationship between the two universities.
"UQ and Emory share many research synergies, particularly in the development of treatments for cancer, and we are proud that we have been able to work together to facilitate this landmark investment," Hj said.
A recently completed phase 1b clinical trial of Q-122 undertaken by QUE saw some participants report a 100 per cent reduction in hot flash incidents.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Jun 17